C3N-02290
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 51.73442847
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.420
- MYC_TARGETS_V2+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.380
- MYC_TARGETS_V1+0.370
- ADIPOGENESIS+0.300
- E2F_TARGETS+0.220
- DNA_REPAIR+0.200
- PEROXISOME+0.140
- MTORC1_SIGNALING+0.120
- UV_RESPONSE_UP+0.120
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.470
- ALLOGRAFT_REJECTION-0.440
- INTERFERON_GAMMA_RESPONSE-0.430
- HEDGEHOG_SIGNALING-0.330
- INFLAMMATORY_RESPONSE-0.330
- KRAS_SIGNALING_UP-0.330
- IL6_JAK_STAT3_SIGNALING-0.300
- TGF_BETA_SIGNALING-0.290
- TNFA_SIGNALING_VIA_NFKB-0.280
- IL2_STAT5_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013505 | — | cohortA4 | 0.844 |
| 2 | 513fb61a-1339-45d2-8963-6337e3aff5df | — | — | 0.837 |
| 3 | TCGA-UF-A71A-06A-11R-A39I-07 | — | — | 0.836 |
| 4 | 2d8cab40-0dda-4d6d-a9ba-83a82a7e1c15 | — | — | 0.835 |
| 5 | AUR-AFKF-TTM1-A-1-1-R-A742-41 | — | C | 0.830 |
| 6 | C3N-01024 | — | cohortA1 | 0.828 |
| 7 | 4fd42f6e-b04a-4726-b35f-a19d17a6e7bb | — | — | 0.826 |
| 8 | SRR821468 | GTEX | — | 0.826 |
| 9 | SRR12475110 | — | — | 0.825 |
| 10 | TCGA-XF-A9T0-01A-11R-A39I-07 | — | — | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.080 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.020 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.010 | Inavolisib | — uncovered |